Is eribulin treatment prognostic factor in patients with metastatic breast cancer treated with this drug? Retrospective analysis of a multicentre study
| Autor: | Oruc, Z. and Kaplan, M.A. and Geredeli, C. and Sari, N.Y. and Ozaslan, E. and Aytekin, A. and Elkiran, E.T. and Koca, S. and Dogan, M. and Turan, N. and Yuce, O. and Sevinc, A. and Ercelep, O. and Isikdogan, A. |
|---|---|
| Přispěvatelé: | Mersin City Hospital, Department of Medical Oncology, Mersin Integrated Health Campus, 96015 street, Toroslar, Mersin, 33240, Turkey, Dicle University Faculty of Medicine, Department of Medical Oncology, Diyarbakir, Turkey, Okmeydani Training and Research Hospital, Department of Medical Oncology, Istanbul, Turkey, Ataturk University School of Medicine, Department of Medical Oncology, Erzurum, Turkey, Erciyes University School of Medicine, Department of Medical Oncology, Kayseri, Turkey, Gazi University, School of Medicine, Department of Medical Oncology, Ankara, Turkey, Inonu University, School of Medicine, Department of Medical Oncology, Malatya, Turkey, Marmara University, School of Medicine, Department of Medical Oncology, Istanbul, Turkey, Ankara Numune Training and Research Hospital, Department of Medical Oncology, Ankara, Turkey, Cumhuriyet University School of Medicine, Department of Medical Oncology, Sivas, Turkey, Celal Bayar University, School of Medicine, Department of Medical Oncology, Manisa, Turkey, Gaziantep University, School of Medicine, Department of Medical Oncology, Gaziantep, Turkey, Dr. Lutfi Kirdar Kartal Education and Research Hospital, Department of Medical Oncology, Istanbul, Turkey, Mersin City Hospital, Department of Medical Oncology, Mersin, Turkey, Atatürk University School of Medicine, Department of Medical Oncology, Erzurum, Turkey, Dr.Lutfi Kirdar Kartal Education and Research Hospital, Department of Medical Oncology, Istanbul, Turkey |
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Popis: | Purpose: This study aimed to analyze prognostic factors for survival and the reliability and the effectiveness of eribulin therapy in metastatic breast cancer (MBC) patients. Methods: A total of 80 patients treated with eribulin in 12 medical oncology centers in Turkey between 2013-2017 were retrospectively evaluated. Sixteen potential prognostic variables were assessed for analysis. Results: The patients had received a median of 5 prior chemotherapy regimens and a median of 3 eribulin cycles for MBC. Median progression-free survival (PFS) was 5.5 months (95% Cl: 4.1-7.8) and median overall survival (OS) was 11 months (95 % Cl: 6-15). Multivariate analysis showed that eribulin treatment line was shown to have independent prognostic significance for PFS. PFS difference was demostrated in patients who received 3 chemotherapy lines for advanced disease compared to those who had more than 3 chemotherapy lines [median PFS; 3 lines: 8.6 months (6.2-11) and >3 lines: 4.6 months (3.7-4.6) p=0.00]. The clinical benefit rate (CBR) was 52.5 and 35% in patients treated with three lines and with >3 previous chemotherapeutic regimens. Most common toxicities were neutropenia (62.5%), fatigue (52.5%), alopecia (50%) and nausea (37.5%). Conclusions: Eribulin treatment line was identified as in-depedent prognostic factor for PFS in MBC patients. © 2019 Zerbinis Publications. All rights reserved. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|